Navigation Links
Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
Date:3/18/2013

to $25.3 million of funding over seven years, is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for the quarter and year ended December 31, 2012, were $4.4 million and $18.0 million as compared to $4.2 million and $20.0 million for the same periods in 2011. General and administrative expenses for the quarter and year ended December 31, 2012, were $2.9 million and $10.8 million, compared to $3.3 million and $12.0 million for the quarter and year ended December 31, 2011.

Net Loss Attributable to Common Stockholders The $4.4 million increase in net loss attributable to common stockholders for the year ended December 31, 2012, compared with the year ended 2011 resulted primarily from a significant (non-cash) change in fair value of common stock warrants, based on a required quarterly mark to market adjustment to reflect changes in the Company's stock price, the change in fair market value of our investment in VGX International, and a decrease in grant revenue.

Capital Resources During the year ended December 31, 2012, the Company sold 9,344,611 shares of common stock under its ATM common stock sales agreement for net proceeds of $5.3 million.

As of December 31, 2012, cash and cash equivalents plus short-term investments in certificates of deposit, mutual funds, and municipal bonds were $13.8 million compared with $30.3 million as of December 31, 2011.

Subsequent to year end, the Company sold 8,222,966 shares of common stock under its ATM common stock sales agreement for net proceeds of $5.6 million.

On March 7, 2013, we closed an underwritten offering of 27,377,266 shares of our common stock and warrants to purchase an aggregate of up to 13,688,633 shares of common stock. The shares and warrants were sold in units at a price of $0.55 per unit, with each unit consisting of one share of common stock and a w
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... June 22, 2011 CardioFocus, Inc., developer of the ... atrial fibrillation (AF), announced today that its technology will ... upcoming European Heart Rhythm Association (EHRA) EUROPACE 2011 congress, ... EAS is a unique catheter ablation technology that incorporates ...
... SHENZHEN, China, June 22, 2011 /PRNewswire-Asia/ -- Winner Medical Group ... Company"), a leading manufacturer of medical dressings, medical disposables and ... today announced the Company,s management team will present at the ... to be held on June 27 and 28, 2011 at ...
Cached Medicine Technology:CardioFocus HeartLightâ„¢ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011 2CardioFocus HeartLightâ„¢ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011 3Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... By looking at ... structure and function, personality, life experiences and genetics, researchers can ... binge drinking within the next two years. Impulsivity, hopelessness, sensation-seeking ... events and a family history of drug use contribute to ... child had had a single drink at age 14 was ...
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... is widespread among U.S. adolescents and young adults ages 14 ... the University at Buffalos Research Institute on Addictions (RIA). ... the first national survey of its kind show problem gambling ... (for example, gambling more than you intended or stealing money ...
... Vascular Insights LLC announced,today that it has received ... (FDA) to market its ClariVein(TM) infusion catheter for,infusion ... ClariVein(TM) is a percutaneous, 2 2/3 Fr (0.035") ... that enhances fluid dispersion in the,treatment area., ...
... 6 Epitomics, Inc. announced,today that its Hangzhou ... and production of its novel line of rabbit ... standard for quality management and ultimately the finest ... Dr. Guo-Liang Yu,President and CEO of Epitomics, Inc., ...
... Care Management: Making a ... Difference Today and Tomorrow, HARRISBURG, ... Medical Officer, will deliver the clinical keynote,address on Wednesday afternoon, ... the World of Care Management. Dr. Petrulis will,present Care Management: ...
... at dilated veins seen with cirrohosis but aren,t sensitive ... New noninvasive methods to detect esophageal bleeding in people ... Italian and American researchers. , About 25 percent of ... are extremely dilated veins commonly seen with cirrhosis. Variceal ...
... bowel movement, serious complications can follow, experts note , , ... have identified a marker that might predict which pregnant ... is essentially a baby,s first bowel movement, excreted in ... It is considered a sign of fetal distress. A ...
Cached Medicine News:Health News:Estimated 750,000 problem gamblers among America's youth 2Health News:Estimated 750,000 problem gamblers among America's youth 3Health News:Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies. 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Noninvasive Procedures Show Promise for Esophageal Bleeding 2Health News:Doctors Discover Marker for Meconium Passage During Delivery 2
The most versatile 90 full field perimeter for static- and kinetic perimetry. It incorporates standard White-on-White and Blue-on-Yellow static perimetry. Octopus 101 covers all the needs in clinics ...
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... The Humphrey Matrix represents the ... Using frequency doubling technology, the Humphrey ... thorough visual field evaluation and assess ... enables you to provide complete long-term ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
Medicine Products: